NCT06382051Recruiting
Modifying PEST for Psoriatic Arthritis Screening
A Multicenter, Prospective, Study to Evaluate the Impact of Modifying the Validated Psoriasis Epidemiology Screening Tool (PEST) on the Potential Diagnosis of Psoriatic Arthritis in Adult Patients With Moderate-to-severe Plaque Psoriasis in Canada ("ScreenX")
Source: ClinicalTrials.gov · Last updated 28 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 502 (estimated)
- First submitted
- 19 Apr 2024
- Start date
- 23 Jan 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT06382051
What you commit to
- Study type: Interventional
- Planned participants: 502
- From 23 Jan 2025 to the primary completion date, 31 Dec 2026
- 21 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have previously screened positive for PsA through PEST.
- Patients treated with a bDMARD for moderate-to-severe plaque PsO or any other medical condition within the last 6 months prior to patient enrollment.
Other
- Patients who have been diagnosed with PsA.
- Patients who have been diagnosed with inflammatory arthritis unrelated to PsA (rheumatoid arthritis, reactive arthritis, enteropathic arthritis, axial spondyloarthritis)
Who the study is looking for
- Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, according to physician's clinical judgement at the time of patient enrollment.
- Adult patients at the time of informed consent signature
- Patients able to understand and willing to comply with protocol requirements, instructions, and restrictions
- Residents of Canada
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (21)
Sites in registry order. Save your city in your profile to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.